Remove Licensing Remove Packaging Remove Trials
article thumbnail

Royalty Pharma and Revolution Medicines Sign Funding Deals Worth Up to $2 Billion

The Pharma Data

securing a funding package of up to $2 billion. Clinical Pipeline Highlights: Daraxonrasib in Focus Daraxonrasib is currently undergoing Phase 3 clinical trials for two of the most aggressive and treatment-resistant cancer types: pancreatic cancer and non-small cell lung cancer (NSCLC), both driven by RAS mutations.

article thumbnail

Lexeo to help launch spinout around RNA drugs for the heart

BioPharma Drive: Drug Pricing

Published June 24, 2025 Gwendolyn Wu Senior reporter post share post print email license Lexeo Therapeutics and two life sciences investors are working together to launch a startup to develop cardiac RNA therapies. You can unsubscribe at anytime. Both programs are in early human studies.

RNA 219
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Private equity firms back PCI Pharma in bet on drug production

BioPharma Drive: Drug Pricing

Published July 14, 2025 Ben Fidler Senior Editor post share post print email license Bain Capital, Kohlberg and Mubadala joined to invest in biopharmaceutical CDMO PCI Pharma on July 14, 2025. PCI helps biopharmaceutical companies manufacture and package drug products used in clinical trials as well as commercially.

article thumbnail

Setting up Sitecore Content Serialization using Sitecore for Visual Studio (SVS) – GUI

Perficient: Drug Development

SVS requires a license; we can utilize the same license as Sitecore TDS. If you don’t have a license, then you can purchase from the TDS site. For learning purposes, you can request a trial license as well. Step 05: After submission, you need to download a package and install it.

article thumbnail

The rise of GLP-1 drugs: Transforming weight loss treatment

BioPharma Drive: Drug Pricing

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales.

Treatment 130
article thumbnail

What FDA’s Newest Gene Therapy Approval Tells Us About Durability: How Long is Long Enough?

FDA Law Blog: Drug Discovery

This product was developed by uniQure prior to being licensed to CSL Behring. The gene therapy demonstrated that it increased Factor IX (“FIX”) plasma levels at 6 months, the original primary endpoint of the Phase 3 trial. Essentially, FDA was now asking for 18 months of data following treatment.

Therapies 119
article thumbnail

RECOVERY Trial Data Monitoring Committee Recommends Continuing Evaluation of REGN-COV2 in All Hospitalized Patients

The Pharma Data

Regeneron announced today an update from the independent data monitoring committee (DMC) for the United Kingdom-based RECOVERY trial evaluating REGN-COV2 in hospitalized patients with COVID-19. The DMC letter is available here: [link]. Department of Health and Human Services under OT number: HHSO100201700020C.